Late last year, the chief leasing officer for Kilroy Realty Corp. saw more biotech companies showing interest in the second ...

One of the main arguments made for bodyoids is that they could provide spare human organs. There’s a huge shortage of organs ...

Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, bolstering the company’s argument that the siRNA candidate has an edge over ...

Top FDA official Peter Marks was forced to resign as the director of the Center for Biologics Evaluation and Research.

AbbVie, Danaher, Thermo Fisher Scientific, Cognizant Technology Solutions, Vertex Pharmaceuticals, Alnylam Pharmaceuticals, ...

the Novo Nordisk-partnered biotech has struck a deal with its founder Flagship Pioneering that could see it file for bankruptcy and lay off up to 17 people. Story Jan. 29 - Cargo Therapeutics ...

The Boston biotech is also looking into "strategic options" after its only clinical-stage drug showed disappointing Phase 1 ...

The startup is bringing into Phase 1 testing an experimental treatment it says could be more effective than marketed ...

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and ...